Abdominothoracic Muscular Tone in Functional Dyspepsia

Sponsor
Hospital Universitari Vall d'Hebron Research Institute (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05417204
Collaborator
(none)
30
1
2
14.4
2.1

Study Details

Study Description

Brief Summary

Background. Patients with functional dyspepsia report symptoms after eating without detectable cause. A recent proof-of-concept study demonstrated that in healthy subjects, the activity of the abdominal walls influences perception of digestive sensations, specifically, intentional abdominal distension (by a maneuver of diaphragmatic contraction) increased bloating sensation in response to a probe meal.

Aim. To determine the role of the abdominothoracic muscular activity on symptoms of functional dyspepsia.

Design. Parallel study in dyspeptic patients who have an abnormal somatic response to a probe meal (experimental group), and patients who do not (control group), comparing the effect of abdominophrenic biofeedback on dyspeptic symptoms. The probe meal will consist in stepwise ingestion of a comfort meal (hot ham and cheese sandwich plus orange juice) up to maximal satiation.

Intervention. A standard biofeedback technique (3 sessions over a 4-week period) directed at controlling the muscular activity (postural tone) of the abdominal walls, will serve as active intervention in the experimental group, and as a sham intervention in the control (active comparator) group.

The study outcomes will be measured before, immediately after and at 6 months after biofeedback: 1) Clinical symptoms measured by scales during 7 consecutive days. 2) Responses to the probe meal: (a) sensations measured by scales; (b) changes in girth by adaptive belts; (c) diaphragmatic position by abdominal ultrasound.

Relevance. The identification of a pathophysiological mechanism of dyspeptic symptoms could serve as an objective marker for diagnosis and as a target for the development of mechanistic treatments.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Abdominothoracic biofeedback
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Adaptive design: a sample size calculation based on the primary outcome will be performed after 30 patients complete the post-intervention evaluation.Adaptive design: a sample size calculation based on the primary outcome will be performed after 30 patients complete the post-intervention evaluation.
Masking:
Double (Participant, Care Provider)
Primary Purpose:
Other
Official Title:
Role of Abdominothoracic Muscular Activity on Symptoms of Functional Dyspepsia
Anticipated Study Start Date :
Jul 18, 2022
Anticipated Primary Completion Date :
Jul 31, 2023
Anticipated Study Completion Date :
Sep 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Correction of abnormal somatic response to a meal

Biofeedback in patients with functional dyspepsia and abnormal somatic response to a probe meal

Behavioral: Abdominothoracic biofeedback
A standard biofeedback technique (3 sessions over a 4-week period) directed at controlling the muscular activity (postural tone) of the abdominal walls, will serve as active intervention in the experimental group, and as a sham intervention in the active comparator group.

Active Comparator: Sham intervention in patients with normal somatic response to a meal

Biofeedback in patients with functional dyspepsia and normal somatic response to a probe meal

Behavioral: Abdominothoracic biofeedback
A standard biofeedback technique (3 sessions over a 4-week period) directed at controlling the muscular activity (postural tone) of the abdominal walls, will serve as active intervention in the experimental group, and as a sham intervention in the active comparator group.

Outcome Measures

Primary Outcome Measures

  1. Postprandial fullness [7 days]

    Change in postprandial fullness (measured on daily postprandial fullness scales graded from 0, i.e., not at all, to 10, i.e., extremely severe) during 7 consecutive days before and immediately after intervention.

Secondary Outcome Measures

  1. Tolerance of a probe meal [60 minutes]

    Change in the amount of a probe meal tolerated (Kcal consumed) before and after intervention.

  2. Digestive well-being after a probe meal [60 minutes]

    Change in digestive well-being after a probe meal (measured on a scale graded from -5, i.e., extremely negative, to +5, i.e., extremely positive) before and after intervention

  3. Postprandial fullness after a probe meal [60 minutes]

    Change in postprandial fullness after a probe meal (measured on a scale graded from 0, i.e., not at all, to 10, i.e., extremely severe) before and after intervention

  4. Abdominal distension in response to a probe meal [60 minutes]

    Changes in the girth response to a probe meal (measured by adaptive belts) before and after intervention.

  5. Diaphragmatic response to a probe meal [60 minutes]

    Changes in the diaphragmatic response to a probe meal (measured by ultrasound) before and after intervention.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Rome IV Criteria for functional dyspepsia
Exclusion Criteria:
  • organic gastrointestinal diseases

  • obesity

  • history of anosmia and ageusia

  • alcohol abuse

  • eating disorders

Age- and-sex-matched healthy subjects will be included in parallel to the 30 first patients, to determine the normal values of the response to the probe meal. Healthy subjects will not undergo the intervention.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospital Vall d'Hebron Barcelona Spain 08035

Sponsors and Collaborators

  • Hospital Universitari Vall d'Hebron Research Institute

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Hospital Universitari Vall d'Hebron Research Institute
ClinicalTrials.gov Identifier:
NCT05417204
Other Study ID Numbers:
  • PR(AG)163/2022
First Posted:
Jun 14, 2022
Last Update Posted:
Jul 6, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Hospital Universitari Vall d'Hebron Research Institute
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 6, 2022